Table 2

Pre-intervention discordance rate between investigators and blinded independent centralized review

Location of discordant progressive disease (n=31)*Location of concordant progressive disease (n=46)*
Target lesion progression (n=1)† Non-target lesion progression (n=9)† New lesion progression
(n=45)† 		New lesion progression (n=132)†

  • Peritoneum (peritoneal implant along the stomach, increase to 16 mm [from 10 mm at baseline])

  • Peritoneum, n=3 (33%)

  • Lymph nodes, n=2 (22%)

  • Pelvis, n=1 (11%)

  • Ascites, n=1 (11%)

  • Stomach, n=1 (11%)

  • Pleural effusion, n=1 (11%)

  • Peritoneum, n=11 (24%)

  • Pelvis, n=9 (20%)

  • Lymph nodes, n=7 (16%)

  • Ascites, n=6 (13%)

  • Stomach, n=3 (7%)

  • Liver, n=2 (4%)

  • Pleural effusion, n=2 (4%)

  • Breast, n=1 (2%)

  • Lung, n=1 (2%)

  • Other, n=3 (7%)

  • Peritoneum, n=50 (38%)

  • Pleura, n=29 (22%)

  • Lymph nodes, n=12 (9%)

  • Liver, n=11 (8%)

  • Ascites, n=5 (4%)

  • Colon, n=4 (3%)

  • Brain, n=2 (2%)

  • Pelvis, n=2 (2%)

  • Pleural effusion, n=2 (2%)

  • Stomach, n=1 (1%)

  • Other, n=14 (11%)

  • *Number of patients with discordant or concordant progressive disease where each patient could have progressive disease composed of multiple lesions across the categories listed.

  • †Number of lesions considered for progressive disease/non-progressive disease by investigator or blinded independent centralized review.